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Abstract
Background: Prophylactic treatment is an important but under-utilised option for the management of migraine.
Patients and physicians appear to have reservations about initiating this treatment option. This paper explores the
opinions, motives and expectations of patients regarding prophylactic migraine therapy.
Methods: A qualitative focus group study in general practice in the Netherlands with twenty patients recruited
from urban and rural general practices. Three focus group meetings were held with 6-7 migraine patients per
group (2 female and 1 male group). All participants were migraine patients according to the IHS (International
Headache Society); 9 had experience with prophylactic medication. The focus group meetings were analysed using
a general thematic analysis.
Results: For patients several distinguished factors count when making a decision on prophylactic treatment. The
decision of a patient on prophylactic medication is depending on experience and perspectives, grouped into five
categories, namely the context of being active or passive in taking the initiative to start prophylaxis; assessing the
advantages and disadvantages of prophylaxis; satisfaction with current migraine treatment; the relationship with
the physician and the feeling to be heard; and previous steps taken to prevent migraine.
Conclusion: In addition to the functional impact of migraine, the decision to start prophylaxis is based on a
complex of considerations from the patient’s perspective (e.g. perceived burden of migraine, expected benefits or
disadvantages, interaction with relatives, colleagues and physician). Therefore, when advising migraine patients
about prophylaxis, their opinions should be taken into account. Patients need to be open to advice and
information and intervention have to be offered at an appropriate moment in the course of migraine.
Keywords: Migraine, Prophylaxis, Focus groups, Primary care, Physician-patient relationship
Background
Primary care is an important setting for the manage-
ment of migraine and in many countries most migraine
consultations occur in this context [1]. In the Nether-
lands, migraine is mainly managed in primary care and
95% of prescriptions for triptans are issued in this set-
ting [2].
Prophylactic therapy is an option for patients with fre-
quent or long-lasting migraine headaches [3-8]. The
results of 6-12 months of preventive treatment are that
in about 50% of patients the attack frequency decreases
by 50%. Also, the attacks are often less severe [9]. Drop-
out by adverse events is around 5%[10], drop-out due to
ineffectiveness is unknown in usual care.
Dutch GP guidelines on headache recommend dis-
cussing prophylactic therapy with patients who suffer
(on average) 2 or more attacks each month [11]. Despite
it being a safe and more or less effective treatment
option, only 7-13% of the migraine patients receive it
[7,12] and the benefits are not widely accepted. Little is
known about the opinions of GPs and patients regarding
prophylaxis, or the determinants behind decisions
whether or not to start prophylaxis.
This qualitative study explores the opinions, motives
and expectations of migraine patients about prophylactic
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migraine therapy. A similar study focusing on GPs’ opi-
nions is reported separately.
Methods
Recruitment
Three focus groups of migraine patients were formed, 2
from urban areas and 1 from a rural area. Patient selec-
tion was based on pre-specified criteria, aiming to reflect
a broad range of experience (from young to old), gender
(separate groups for males and females), attack fre-
quency ≥ 2 attacks/months) and pain level (≥ 6 on a
scale of 10 matching migraine,1 being almost no head-
ache and 10 being the worst headache ever). Our goal
was to achieve a diversity of migraine patients, corre-
sponding to general practice and with a sufficiently high
frequency to be eligible for preventive therapy [12,13].
The study was approved by the Ethics Committee of the
Leiden University Medical Centre.
One group of 7 females and a second group of 6
males were recruited from 5 urban primary care health
centres or group practices. See patient characteristics in
Table 1. We selected patients based on the diagnosis
migraine and all these patients used prescribed medica-
tion for acute treatment. Thirteen patients had con-
sulted their GP or a neurologist for their migraine (2
groups). A third group, comprising 7 females from a
rural area, was recruited by a researcher investigating
consumer behaviour. In this group each participant was
approached by telephone and selected if they had
migraine according to the IHS criteria. In this group 2
participants had not received any medical supervision
yet.
The application form contained two questions on
migraine (severity and frequency), one on the level of
education and one about the number of hours in paid
work. Based on this application form, the researcher
made a comparison with national data on migraine
patients in general practice [12]. Regarding the severity
and frequency of the migraine, the composition of the
three groups corresponded well with the average charac-
teristics of migraine patients in Dutch general practice.
The subject mentioned on the invitation was migraine
headache in general, without a specific indication of our
interest in preventive treatment.
Data generation
The focus group meetings were chaired by an indepen-
dent moderator experienced in focus group research.
The principal investigator (FD) observed all meetings
from an adjacent room via a monitor with sound, but
had no influence on the discussions. The moderator
used a specially prepared interview guide (compiled by
AKN and FD) which started with an introduction and
familiarization, followed by discussion on the character-
istics of the patients’ migraine experience (e.g. age at
onset, changes in migraine over time, treatment for
attacks, and treatment goals, etc.). Prophylaxis was dis-
cussed, including the advantages and disadvantages, and
the patients’ experiences and attitudes towards preven-
tive medication. In all focus groups sessions a topic list
was used, which included some provocative statements
to stimulate discussion and the exchange of ideas. The
quantitative data listed in the results section are based
on this topic list. All sessions were digitally recorded on
DVD.
Data analysis
The recordings were analysed independently by three
researchers (FD, AKN and BA). Because the DVD
recordings provided the most detailed information on
both verbal and non-verbal communication, these served
as the primary data source [14-16]. The researchers used
regular DVD-reading software with good on-screen for-
ward/backward and other search possibilities. The
DVDs allowed both hearing and seeing of non-verbal
indications as to whether or not an opinion was sup-
ported by others in the group. The three investigators
individually identified ‘themes’, that is remarks contain-
ing information on prophylactic therapy, or relevant or
closely related to it. A transcript was made of all the
comments by the participants on preventive treatment.
Subsequently these comments were grouped
Table 1 Patient characteristics, 2 female and 1 male
groups
Total
N =
20
Female
1
n = 7
Male
n =
6
Female
2
n = 7
Pain score* (1-
10)
8.4 8.2 8.4 8.6
Attack freq./
month
2 - 5 16 6 5 5
≥ 5 4 1 1 2
Age < 25 4 2 - 2
25 - 50 11 3 4 4
> 50 5 2 2 1
mean 43 yrs 42 yrs 47
yrs
39 yrs
Education level low 3 - 1 2
medium 14 5 5 4
high 3 2 - 1
Paid work (hrs/
wk)
none 5 2 1 2
< 36 8 4 1 3
≥ 36 7 1 4 2
mean (hours/
week)
22 15 29 21
* Pain level during maximum of attack on a 1-10 numeric scale (10 being
unbearable pain)
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independently by three researchers. The identified
themes were written out and then organised into cate-
gories and (sub-) themes by the principal investigator,
according to the rules of ‘thematic analysis [16-18]’ into
a draft analytical framework. This framework was conse-
cutively discussed and decided upon with the other
members of the team.
When there was disagreement between researchers in
the analysis, the theme was analysed again by the dis-
agreeing researchers and in case of a persisting discre-
pancy consensus was soughed and reached between the
researchers. The analysis was coordinated by the princi-
pal investigator, who did put the remaining questions
each time to both the other researchers. An interpreta-
tive analysis of the data with the help of this framework
enabled the identification of several related but separate
topics of experience and reasoning regarding prophylac-
tic treatment for migraine and a tentative model for
understanding patients’ decision making regarding such
treatment.
Results
Five main categories of themes emerged from the focus
group meetings.
1) Previous steps taken to prevent migraine
With regard to preventive measures, many participants
were concerned that migraine was not well understood,
and some found it hard to rely on prophylactic therapy
because the mechanism was still unclear to them.
Almost all patients had experimented with beha-
vioural, lifestyle or dietary actions, mostly without suc-
cess and later therefore abandoned. However, some
patients continued with these behaviours, even when
they believed that they probably provided no benefit.
Many participants avoided certain foods and other types
of products. Some used specific products in order to
promote their health.
’Stabilizing the biological clock’, i.e., developing a
stable day-night rhythm, was a widely used precaution
by more than half of participants. Interventions were
often supported by their physicians. For some patients,
prophylaxis was the last resort.
“I ‘did’ the whole alternative circuit. I tried every-
thing. Only after all that was I ready for prophy-
laxis.” (Group 1, PT 1)
Many types of complementary medicines had been or
were being used. Most patients believed that although
prophylactic treatment is only moderately effective, it is
still more effective than complementary therapies. Using
a complementary therapy often hampered patients from
considering prophylaxis; they were waiting for the
effects of the complementary interventions. Once com-
plementary therapies had failed, they were more willing
to try regular therapies.
“In the beginning, when my migraines were first diag-
nosed, we tried everything and every therapy to treat
the attacks. Later on, I stopped making appointments
for my migraines, I was so disappointed ... and I
tried everything myself, avoided all kinds of food,
gulped down vitamins and other supplements,
relaxation therapies, etc., etc.” (Group 3, PT 5)
2) Satisfaction with current migraine treatment
Migraine patients differed in how they determined
whether or not they were satisfied with their treatment.
Some patients were satisfied when they were able to
keep on functioning at work or at home, others were
only satisfied when the headache disappeared.
A few participants kept a highly structured diary to
ascertain whether there were any factors that influenced
their migraine. Keeping a diary made patients more
accessible to prophylactic medication.
“My GP gave a kind of brochure; later on I continued
keeping record of my headaches. I think that’s very
important; noting parallel things, food and so, look-
ing back whether medication works.” (Group 1, PT 1)
According to the patients, preventing the overuse of
attack treatment was only occasionally considered by
the GP. According to the patients, almost no GP used
that argument in the discussion about whether or not to
start preventive treatment. Remarkably, some patients
who used excessive attack treatment mistakenly called it
‘prevention’. In their incorrect but exemplary way of
thinking, they considered it to be prophylaxis because
they used the attack treatment before a migraine attack
occurred. Some patients showed very limited awareness
about the risks of overuse of attack treatment.
“I already take so many medications, so don’t do that
preventive thing to me. When I feel a headache com-
ing, I just take a tablet and that’s prevention to me.”
(Group 2, PT 3)
Most patients agreed that effective migraine treat-
ment consists of effective attack management in addi-
tion to effective prophylaxis. More than half of the
patients wanted to reduce the use of attack treatment,
because they felt they were using too many triptans or
painkillers. However, patients still focused on the
importance of attack treatment; prophylaxis took sec-
ond place. This focus on attack treatment hampered
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their thinking about other strategies to reduce the bur-
den of migraine.
“I’m afraid of the side-effects of triptans; that’s mak-
ing me more open to prophylaxis.” (Group 1, PT 5)
The feeling of being in control of the migraine and
not being controlled by it was considered a very impor-
tant factor. Participants accepted a high frequency of
migraine and/or long-lasting attacks as arguments for
prophylaxis. However, the vast majority believed that if
the attack treatment was extremely effective, there
would be no need for prophylaxis. This was irrespective
of the number of attacks and was in relation to what
patients found ‘normal’ for them.
“I’m not stuffing my body with medication when I
have an attack 3 times a month, even if it is terribly
intense, but when it’s good treatable.” (Group 2, PT
7)
3) Taking the initiative for prophylaxis
Although not every patient had personal experience with
migraine prophylaxis, almost everyone knew about its
existence. Most patients received information from
family members, physicians, the Internet, the media or
pharmacists. Many participants had searched the Inter-
net for specific information on prophylaxis and encoun-
tered both positive and negative information such as
stories of patients who have had a lot to benefit from
prophylaxis and others who had no good effect and suf-
fered from significant side effects.
“I’m using preventive therapy now. I didn’t hear any-
thing about it from the doctor ... I found out myself
that something like that was available. It was in a
women’s magazine, not via the GP. I’m unhappy
about that...”(Group 3, PT 7)
Testimonies of other patients or information of a
patient headache association was not clear enough or
too ambiguous to make a first step. It did not have a
direct influence on their own health-seeking behaviour.
“Anti-epileptics, that sounds dreadful. The sort of
thing you associate with lying on the ground with
foam around your mouth.” (Group 2, PT 3)
There was no consensus as to who should take the
initiative for prophylaxis. About half of the patients
expected an active approach from their GP. Others
(more urban and/or more highly educated) preferred to
take the initiative themselves. All patients expected that
their GP should be able to discuss the advantages and
disadvantages of prophylaxis.
Patients found it important that discussion about pro-
phylaxis should take place at the appropriate moment.
This was not necessarily at the initial diagnosis, but
when the patient knew more about the impact of
migraine and the effectiveness of attack treatment. The
need for prophylaxis could then be considered within a
more realistic context.
“I never wanted it; I’m not a pill swallower. But I
find it terrible to have to call my colleagues that I
have another attack again. Then they stare at me
with negatively loaden, piercing eyes. And I have
started to think differently about daily treatment.”
(Group 2, PT 6)
Prophylaxis was often discussed when patients indi-
cated they were no longer able to cope with the head-
ache attacks.
“My migraines were so severe that I went to the doc-
tor ... I couldn’t do anything but cry. He tried to com-
fort me and offered prophylaxis.” (Group 3, PT 4)
For a few participants, the initiative for prophylaxis
was taken by the GP based on the amount of prescribed
attack medication; these GPs actively monitored the use
of triptans and painkillers. When confronted with such
an active approach, the patients were initially cautious
but subsequently regarded the GP’s intervention as posi-
tive. Ultimately, almost all patients desired to have their
own control over the final decision.
“Sometimes I’m afraid he’ll phone again ... because I
take too much medication. I once phoned for a repeat
prescription, but the doctor called back and said:
You’ve used too much this month. Then he men-
tioned preventive therapy. It feels OK, that he’s con-
cerned about me.” (Group 1, PT 5)
4) Assessing the advantages and disadvantages of
prophylaxis
From the patient’s perspective, the decision to start pro-
phylaxis is complex. There is a wide range of perceived
advantages and disadvantages, migraine patterns often
vary, and the underlying concerns also differ.
“The pattern of attacks of my migraine is too weird
to be able to figure out whether prophylaxis will help
me or not.” (Group 3, PT 2)
“Accepting prophylaxis is difficult, because my attacks
sometimes stay away for a long time. It’s sometimes
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months before I have another attack, but once they
start they’re very frequent.” (Group 3, PT 3)
“I’m now using so many triptans ... this can’t be a
good thing.” (Group 3, PT 2)
“I just don’t want to do it. I’m very anti-drugs.”
(Group 3, PT 1)
When considering prophylaxis, all patients experi-
enced negative or obstructive elements, as well as posi-
tive factors. Participants had differing views on this
subject, some mainly emphasised the positive aspects
and others mainly the negative aspects.
The most important negative factors were the fear of
side-effects, the assumption that prophylaxis will have
little impact, and the feeling of becoming a chronic
patient. The issue of ‘becoming a chronic patient’ was
expressed in all sessions, and about 50% of the patients
associated the use of prophylactic drugs with ‘old age’
and ‘chronic disease’. Participants emphasised that they
did not feel like a ‘patient’ in between the migraine
attacks, so it did not feel appropriate to use medication
on a daily basis. Despite a high impact of migraine and
although many (daily) preventive measures and beha-
vioural adaptations has been adopted, the use of prophy-
lactic drugs was not easily accepted.
More than half of the patients stated that daily use of
tablets for migraine would make them feel emotionally
unhealthier. Other negative factors included the fear of
drug dependency, a low assessment of their own capa-
city for compliance, and the negative reactions of per-
sons in their direct surroundings.
“If I were to take tablets every day, I’d feel like I’m a
patient. Now I just have a headache sometimes ...
actually it’s many times.” (Group 3, PT 3)
“I think I’d forget it (medication) so often that it
wouldn’t be effective.” (Group 3, PT 7)
“I’m afraid of becoming dependent on those drugs.”
(Group 3, PT 2)
“It’s something in the head about not wanting to take
tablets every day.” (Group 2, PT 4)
“When you receive preventive therapy for something,
people think you’re a pitiful case.” (Group 2, PT 6)
“The question is: how does migraine affect your life. I
don’t want migraine to affect my life, and taking
drugs every day would have a major effect on my
life.” (Group 1, PT 6)
The factors that contribute to positive decision appear
to rest on a more calculated way of thinking or
approach; weighing the advantages against the disadvan-
tages and assessment of the degree of effectiveness.
Half of the participants had benefited from prophy-
laxis. The main positive benefits were a reduction in the
burden of migraine with an increase in the range of abil-
ities; this was particularly important when the impact
was high. Other positive features were the ease of
administration, an overall general gain in health, a
reduction in acute medication, less confrontations with
the GP in case acute medication was used excessively,
and less pressure from others close to them. When the
benefits were clearer, patients were able to accept pro-
phylaxis or were at least willing to try it. Most of the
patients stated they would accept daily drug intake if
their migraine frequency would be halved.
“I don’t care what I have to do; I’d do anything to get
rid of my headaches.” (GR 2, PT 4)
“If it worked for 100%, I would certainly join the
users!” (Group 3, PT 3)
“With prophylactic drugs you’re able to participate
much more in sport activities - which I enjoy very
much.” (Group 1, PT 4)
“If somebody said to me: “The migraines will disap-
pear if I cut off your hand”, then I’d say: Cut off my
whole arm!” (Group 3, PT 3)
Many patients anticipated reimbursement problems
with the healthcare insurance companies when receiving
prophylactic therapy (in fact, in the Netherlands, all costs
of prophylactic therapies are fully covered by healthcare
insurance for all patients). Patients who had experience
with prophylaxis reported that they had no problems with
health insurance or the financial side of treatment costs.
Apart from the duration of the attack another impor-
tant factor was the situation involved, e.g. being at
school, at work, or with friends or family. For similar
attack rates the perceived need for prophylaxis differed
between patients.
Not being able to take care of others was a strong
positive factor for prophylaxis. Apart from the impact of
migraine on themselves also the impact on other per-
sons for whom they are responsible (e.g. children, family
members, colleagues, etc.) was an important argument
for preventive treatment.
“I can’t even make it to the meetings of my sports
club. I might manage it once, but the second, third
and fourth time they wouldn’t understand. When you
feel that negative impact from migraine, then you
really want to start thinking about preventive treat-
ment.” (Group 3, PT 4)
5) The relationship with the physician and the feeling to
be heard
At the time of diagnosis, being taken seriously about the
burden of the migraine and acknowledgement of their
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suffering was considered most important. But this was
not the appropriate time when patients were interested
in prevention. Many migraine patients felt there was a
limit to the extent to which their physician is able to
comprehend the burden they bear. They considered that
their GP unable to imagine how difficult it is to experi-
ence a migraine attack, whereas others mentioned a
sympathetic response from their GP. Patients indicated
that at a later stage a good empathetic relationship with
the doctor was important for the acceptance of preven-
tion.
“He (GP) was really concerned about me, about the
enormous number of attacks I had. That was good
and very considerate of him.” (Group 1, PT 4)
“I think that he (GP) thinks: what on earth can I do
for you anyway...” (Group 2, PT 2)
“I found that now something really has to be done ...
so I went to the doctor. He said: It sounds like classic
migraine; we’ll see what we can do. I should have
done this much earlier ... at last I felt that someone
understood.” (Group 1, PT 2)
“There’s always that fear of the next attack, and my
family doctor seemed to understand that fear. First
and foremost, you have to be taken seriously by your
doctor.” (Group 1, PT 1)
An important influence was the way their GPs treated
them. Positive factors in promoting prevention were
having a positive interaction and the feeling being taken
seriously. On the other hand, being dissatisfied about
the approach of the physician hampered the willingness
to consider prophylaxis.
“Primarily I want to be taken seriously, but I can not
complain. He’s handled it well, with the start of pre-
ventive treatment.” (Goup1 PT 5)
“If you have more than two attacks a month, they
just give you a prescription for anti-epileptics and -
before you know it - you’re outside again.” (Group 3,
PT 6)
Discussion
Summary of main findings
The present study describes patients’ subjective opinions
about prophylaxis as a treatment option for migraine.
A number of conditions that must be met before pre-
ventive therapy is accepted and that these often are
related to each other (Figure 1). These conditions can
be patient related, clinician related or be related to the
disease or the disease process. Knowledge on the impor-
tance of these issues for the decision making of patients
is crucial for physicians dealing with migraine patients
in daily practice.
Patients indicate a number of important factors in
favour of the use of prophylaxis related to the perceived
burden of migraine; a high frequency of attacks, severe
attacks, and lack of effectiveness of attack treatment.
These are characteristics of the migraine itself, on which
physicians do not have much influence (however they
have certainly on proper attack treatment). The patient
makes a balance of pros and cons. Expectations of the
beneficial effects, fear of side effects and drug dependency
and negative health feeling in case of daily use of medica-
tion, play a considerable role in making this balance.
The willingness to try prophylaxis increased after other
interventions had been tried (e.g. dietary changes, changes
in lifestyle or previous complementary treatments).
Patients prefer strongly to take the decision themselves
and want to have responsibility themselves. The individual
history of earlier interventions is pivotal. Several factors
increase the resistance to accepting prophylaxis, such as
changing the scope from seeing migraine as an intermit-
tent to seeing it as a chronic disease.
When weighing the facts and reaching a decision on
prophylaxis, the physician has a major influence, espe-
cially by providing relevant information. In the process
of getting more insight on their migraine, patients feel
that the physician can be helpful. Patients attach great
importance to a good and trusted relationship with the
physician and often prefer an active approach.
It is important to acknowledge that a patient is going
through a process, and in time tend more and more
towards a decision. It takes time to realize that one has
a severe problem with migraine and that the migraine
has a large impact. Keeping a diary can provide such an
insight in an earlier stage [19]. From the management
perspective, patients need to be receptive to the idea of
prophylaxis at the right moment in their migraine
history.
Study strengths and limitations
This focus group research aimed to explore opinions
through a purposeful sample covering a range of sub-
jects and doesn’t provide numbers and clear conclusions
such as quantitative research.
We decided to have separate male and female groups
based on the assumption that their approaches to
migraine differ, and that a mixed group may inhibit the
exploration of some key elements of migraine for
woman, such as a relation with menstruation.
Saturation of themes occurred within the three
groups, when no new themes arose that had not been
included in our topic guide. Within the groups, a diver-
sity of approaches was found. For example, the urban
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group was more highly educated and displayed more
resistance to prophylaxis, and needed a more rational
and evidence-based requirement for its introduction.
The rural group had a more passive attitude and indi-
cated more acceptance to the propositions from their
physician.
A weakness of the present study is that it was con-
ducted in the Dutch language and is reported in English.
Qualitative studies aim to capture meaning from the
narratives of respondents and some loss and/or distor-
tion may have occurred in the translation process. How-
ever, we had the Dutch texts translated by two
experienced translators and from the perspective of
migraine a native English speaking expert physician on
migraine looked into the patient remarks.
Comparison with other studies
Parallel to this study another qualitative study from the
same research group, also on prophylaxis for migraine,
explored the attitude of GPs [20]. That study confirmed
the complexity of the decision-making process, which
from the perspective of the GP was also not based on
the impact of migraine alone. Patients and GPs showed
a similar degree of hesitance, not because of lack of
knowledge or lack of interest, but because of doubts
about effectiveness, side-effects, and the risk of develop-
ing drug dependence.
Of the qualitative studies on migraine, only one has
addressed preventive therapy [21]. In that study by
Rozen, the method (questionnaire) and setting (third-
line centre) were different to ours and all patients had
prior exposure to migraine prophylaxis. The decision
whether or not to start preventive therapy had already
been made, and the questionnaire mainly addressed
side-effects and the choice of drugs. That study provided
no information on its aims or how the decision con-
cerning prophylaxis was made.
Two qualitative studies show agreement with our study
in relation to prevention. One study shows remarkable
similarities on the patient communication with the GP
Figure 1 Major influences in patients’ decisions about preventive treatment in migraine.
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and on the search for complementary therapies by
patients. Because this study is not about prevention, is
does cover the influence of these two issues on prevention
[22]. The other study reports that self-efficacy scores were
positively associated with the use of positive psychological
coping strategies to prevent headaches [23].
Other studies which address patient factors in migraine
do not address prophylaxis and focus on the needs of
migraine patients [24,25], decision-making in migraine
[26-28], the burden of migraine and quality of life [29,30],
perimenopausal headache [31], migraine in midlife women
[32], and pressure on patients related to referral [33], and
therefore have almost no overlap to our study. The ques-
tionnaire study by Kowacs et al. on the patients’ view on
side effects of preventive treatment revealed that side
effects are better accepted by patients with high use or
actual overuse of attack treatment, which is consistent
with our findings [34]. The questionnaire study of Kol et
al. found that 55% of patients with two or more attacks
per month wanted to use prophylaxis, while only 8% actu-
ally used this treatment. This paradox is one of the under-
lying themes in our study [12].
Similar studies have also been conducted with other
chronic diseases. For example, the study of Adams et al.
on acceptance of the preventive treatment for asthma
[35]. Specific for prophylactic asthma treatment is that
it is given even in asymptomatic periods, the inhalation
therapy is visible to others and there is fear for side
effects on the longer term (’steroid fear’). In contrast, in
migraine only patients with frequent and severe attacks
are treated, mainly the side effects on the short term are
feared, and in general patients have no trouble with the
acceptance of the migraine as such. This comparison
shows that migraine has similarities, but also differences
with other chronic diseases. Most likely the opinions of
patients differ per indication.
Conclusions
The benefits of prophylactic medication for migraine are
under-exploited. Future research should focus on the
various aspects involved in decisions about preventive
treatment, as reflected in the present study. An under-
standing by physicians of the patient’s feelings and con-
cerns towards prevention are important for more
effective use of these agents. When advising migraine
patients on prophylaxis it is important to explicitly
address their underlying thoughts and emotions, and to
consider the intervention at an appropriate moment in
the course of the patient’s migraine experience.
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